MIRE Does Not Alleviate Nerve Damage

Published Online: Wednesday, February 1, 2006

Devices that deliver monochromatic infrared energy (MIRE) did not fare any better in reducing foot numbness in individuals with nerve damage due to diabetes, compared with placebo treatments. During the 8-week study, 39 adults with diabetic peripheral neuropathy were randomly treated with MIRE or placebo therapy applied 3 days per week for 4 weeks.

Reporting in Diabetes Care (December 2005), the research team found that 30 minutes of MIRE therapy was not more effective in improving sensation on the sole of the foot, compared with the placebo treatment. MIRE devices were approved by the FDA in the mid-1990s to enhance circulation and reduce pain. The devices have been used in patients with wounds and soft-tissue trauma.

Latest Articles
Donnie Calhoun, RPh, PD, National Community Pharmacists Association (NCPA) Foundation vice president, discusses how pharmacists can prepare themselves and their business before, during, and after a disaster.
Ken Whittemore Jr, Surescript's senior vice president of professional and regulatory affairs, talks about some new transactions available that can help pharmacists.
In case you got caught up in the Thanksgiving holiday rush, here are the top trending stories you may have missed in November:
Bryan Ziegler, PharmD, executive director of Kennedy Pharmacy Innovation Center, provides some resources for community pharmacists to use when implementing new collaborative services with primary care providers.
Latest Issues